Premium
Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy?
Author(s) -
Spencer Kevin,
Berry Esther,
Crossley Jennifer A.,
Aitken David A.,
Nicolaides Kypros H.
Publication year - 2000
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/(sici)1097-0223(200004)20:4<311::aid-pd809>3.0.co;2-p
Subject(s) - trisomy , pregnancy , aneuploidy , medicine , obstetrics , down syndrome , second trimester , first trimester , gynecology , fetus , biology , genetics , chromosome , psychiatry , gene
In a study of 130 first trimester cases of trisomy 21 and 959 controls we have shown that the median MoM for alpha‐fetoprotein (AFP) is lower (0.82) and that for total human chorionic gonadotrophin (hCG) is higher (1.31) than in the control group. For AFP 15.3% of cases were below the 5th centile and for total hCG 19.8% were above the 95th centile. The median shift observed for AFP and total hCG is poorer than that for pregnancy associated plasma protein‐A (PAPP‐A) or free β‐hCG and together with maternal age, AFP and total hCG could only be expected to detect 40% of cases. In combination with PAPP‐A, total hCG would identify 52% of cases, somewhat less than the 67% observed with free β‐hCG and PAPP‐A. However, we have demonstrated for total hCG a significant temporal change in median MoM with gestational age. Before 70 days the median MoM was less than 0.5, between 70 and 83 days this increased to 1.13, and between 84 and 97 days this increased to 1.52. This median shift has significant implications for interpreting previous studies and even more significant implications for detection rates. When population parameters specific to the gestational age in question are used, detection rates with total hCG and PAPP‐A increase from 47% at 70–83 days to 60% at 84–97 days. This observation explains much of the confusion around total hCG in the first trimester and shows the importance of selecting analyte pairs and population parameters appropriate to the time in gestation when screening is performed. Copyright © 2000 John Wiley & Sons, Ltd.